Value20242025TTMSelling/general/admin expenses367.82 M275.8 M275.8 MResearch & development322.38 M195.79 M195.79 MOperating income2.19 B562.16 M562.16 MNon-Operating Income, Total26.8 M27.66 M27.66 MInterest expense, net of interest capitalized———Non-Operating Income, excl. Interest Expenses26.73 M26.67 M26.67 MUnusual income/expense64 K993 K993 KPretax income2.16 B534.5 M534.5 MEquity in earnings———Taxes135.36 M126.15 M126.15 MNon-controlling/minority interest———After tax other income/expense276 K1.35 M1.35 MNet income before discontinued operations2.03 B408.35 M408.35 MDiscontinued operations———Net income2.03 B408.35 M408.35 MDilution adjustment———Preferred dividends———Diluted net income available to common stockholders2.03 B408.35 M408.35 MBasic earnings per share (Basic EPS)-63.54-11.11-11.11Diluted earnings per share (Diluted EPS)-63.54-11.11-11.11Average basic shares outstanding31.9 M36.75 M142.98 MDiluted shares outstanding31.9 M36.75 M142.98 MEBITDA-1.51 B-37.35 M—EBIT-1.8 B-189.25 M—Cost of revenue133.89 M332 K—Other cost of goods sold———Depreciation & amortization (cash flow)291.94 M151.9 M356.1 M
GRAIL Inc
GRAIL, Inc. is an American biotechnology company based in Menlo Park, California founded in 2015 seeking to develop an early cancer screening test for people who do not have symptoms. As a startup it was a subsidiary of Illumina, which bought it outright in 2021.
In June 2021 Galleri launched their liquid biopsy, or multi-cancer early detection test, which they called Galleri test. In 2023 EU regulators ordered Grail to be spun-out from Illumina which was completed on June 24, 2024.